Indications for removal of etonogestrel implant within two years of use in Jos, Nigeria by Muthir, JT & Nyango, DD
November 2010 East african MEdical Journal   461
INTRODUCTION
Implants are sub-dermal contraceptive systems 
developed to increase the contraceptive method mix 
for women intending to use a modern method. They 
release low, stable amounts of contraceptive steroids 
from a suitably inert carrier such as silastic in Jadelle 
or ethylene vinyl acetate in Implanon (1,2). 
 In recent years, the most important trend in 
contraceptive research development has been the 
development of contraceptive methods designed to 
meet the needs of prospective users. Contraceptive 
implants are a proven method of contraception for 
long term prevention of pregnancy (1). Implanon® is 
such a product and is the trademark for etonogestrel. 
It is a progestin-only method of contraception suitable 
for a wide range of women (2). 
 The primary mechanism of action of Implanon@ 
is through ovulation inhibition, and in addition, also 
increases the viscosity of the cervical mucus, thus 
having a dual contraceptive effect. Serum levels 
sufficient to inhibit ovulation are reached within eight 
hours (3). This means that it is efficacious within the 
first day of insertion. 
 The implant has been found to have un-surpassed 
efficacy, independence from user compliance 
and prompt return to fertility after removal. The 
exceptional efficacy has been attributable mainly 
to ovulation inhibition of Implanon®. It provides 
effective, reliable and reversible contraception for a 
maximum period of three years (4,5). Removal of the 
implant before three years is considered premature 
and the indications for such removals require 
evaluation. 
 The aim of the study was to determine the 
indications for these removals, and to be able to 
better counsel and inform new and/or prospective 
clients. 
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ABSTRACT
Background: Implanon® is a new long-term and reversible sub-dermal contraceptive 
implant in Nigeria. It is a single rod containing 68mg of etonogestrel meant to offer 
contraception for three years and marketed by Organon. 
Objective: To determine the indications for removal of lmplanon® rods from clients 
within a two-year period. 
Design: A retrospective review of 30 consecutive lmplanon® removals within the study 
period. 
Setting: The fertility regulation unit of the department of obstetrics and gynaecology 
ofthe Jos University Teaching Hospital, North-Central Nigeria. 
Results: A total of 30 clients requested for and had their lmplanon® rods removed out 
of 669 insertions constituting 95.5% crude continuation rate in the second year. The 
clients were of mean age 31.4 ± 6.2 years, mean parity 2.9 ± 1.8 and mean number of 
living children 2.7 ± 1.6. There was an average weight gain of 1.9 kg. The most common 
indication for removal was menstrual disruption (33.3%). Desire for another pregnancy 
closely followed (30.0%). Weight gain was another indication for discontinuation 
(13.3%). Two women were pregnant at insertion of the implant. There was one failure 
of the method with pregnancy as a result. Spousal disapproval was an indication for 
removal in two cases. 
Conclusion: Like all progestin-only contraceptive methods, menstrual disruption 
was the most common indication for removal of implants. Inadvertent insertion of 
implants with existing pregnancy is of concern and should be avoided as much as is 
possible. In doubtful cases at insertion, this insertion should be deferred or serum 
β-HCG should be assessed to exclude chemical pregnancy. 
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MATERIALS AND METHODS
All the consecutive Implanon® rods removed within 
a three-year period were collated and analysed. 
The duration of study was between May 2006 and 
April 2009. The number of Implanon® rods inserted 
within the study period was also determined from 
the register. The age of the clients in years, parity, 
number of living children, weight at insertion and 
at removal of implants in kilogrammes, duration 
of the use of implant in months, indication for 
removal, marital status, educational status and 
history of previous contraceptive use before accepting 
Implanon® were collated and analysed. Epi Info 
2002® Statistical software was used to determine 
averages, means, standard deviations and frequencies 
of the parameters. The figures were taken to the first 
decimal point. 
RESULTS
Thirty (30) Implanon® rods were removed out of total 
of 669 insertions within the period of review. This gives 
a continuation rate of 95.5% in the first two years. 
The clients were of the reproductive age, between 
19 and 45 years with a mean of 31.4 ± 6.2 years. The 
parity was between one and seven with a mean of 2.9 
± 1.8. They had living children of between one and 
seven with a mean of 2.7 ± 1.6. The clients weighed 
between 42 and 91 kg with an average of 64.8 ± 12.7 
kg at insertion. Their weights at removal ranged 
from 41-100 kg with an average of 66.7 ± 13.3 kg. An 
average weight of 1.9 kg was gained, Table 1. 
Table 1
Parameters of clients with Implanon® removed (n=30)
Parameter Range    Mean (SD)   
Age in years  19-45 31.4 ± 6.2   
Parity 1-7  2.9 ± 1.8   
Number of living children 1-7 2.7 ± 1.6   
Weight at insertion in kg 42-91 64.5 ± 12.7   
Weight at removal in kg 41-100 66.7 ± 13.2
 Within the period of two years of introduction 
of the implants, the thirty women that had the 
implants removed had used lmplanon for duration 
of between 0.5 and 24.0 months with a mean of 13.4 
± 6.8 months. 
 Twenty two (73.3%) of the clients wanted to have 
more pregnancies after discontinuing the implant 
while up to 26.7% did not want any more pregnancies 
and therefore using the implant as a long-term method 
of contraception. 
 Menstrual disorder was the most common 
indication for removal in 33.3%. This was followed 
by the desire for another pregnancy in 30.0%. Four 
clients (13.3%) had the implants removed for weight 
gain. Two (6.7%) women were pregnant at insertion 
of the implant. There was one failure of the method 
with pregnancy as a result. Spousal disapproval and 
headache were indications for removal in two (6.7%) 
cases each. Some of the clients had more than one 
indication for removal of the implant, Table 2. 
 Majority of the clients (66.7%) had used a 
modern method of contraception before accepting 
the Implanon®. The condom and oral contraceptive 
pills (20% each) were the common methods of 
contraception used by the clients prior to accepting 
lmplanon®. Four (13.3%) of them had used another 
implant (Norplant). Ten (33.3%) had not used any 
modern method of contraception before this time, 
Table 3. 
Table 2
Indications for Implanon® removal (n = 35*) * some 
clients had more than one indication for the removal
Parameter  Number (%)   
Menstrual disorders 10 (33.3)   
    Prolonged (5) 
    Heavy flow (3) 
    Irregular flow (2)
Desire for another pregnancy 9 (30.0)   
Weight gain    4 (13.3)   
Pregnant before insertion    2 (6.7)   
Husband wants it removed    2 (6.7)   
Headaches    2 (6.7)   
Others    5 (16.7)   
(Others = Acne - 1, Divorced - 1, Request by mother 
in law - 1, Request by cardiologist - 1, Had total 
abdominal hysterectomy - 1 and Failure of the 
method - 1.) 
Table 3
Previous method of contraception used by the clients (n 
= 35*). *Some clients had used more than one method
Previous method used Number (%) 
No method had been used  10 (33.3)
Condoms 6 (20.0) 
Oral Contraceptive Pills (OCP)  6 (20.0) 
Intrauterine Contraceptive Device (IUD)  5 (16.7) 
Norplant implant  4 (13.3) 
Lactational amenorrhoea method (LAM)  3 (10.0) 
Injectable (Nor-ethisterone enanthate)  1 (3.3) 
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DISCUSSION
Implanon® can be removed on client’s request at 
any time, but after three years it should be removed. 
During the study period, first two years of introduction 
of the implants, 4.5% of the implants inserted were 
removed giving a crude continuation of 95.5%. The 
two- year continuation rate for lmplanon® therefore 
was high among the clients. This was partly because 
of adequate pre-insertion counselling of clients on 
the perceived advantages or benefits which greatly 
outweigh the nuisance effects. This was higher than 
the pooled continuation rate of 90.1% after 12 months, 
84.9% after 24 months for Norplant (6). During this 
period, the expiry time of three years had not been 
reached and therefore none of the indications for 
removal was for exipiry of the device. The thirty 
women whom had the implants removed had used 
Implanon for duration of between 0.5 and 24.0 months 
with a mean of 13.4 ± 6.8 months. 
 The most common indication for removal of the 
implant was menstrual disruption. This constituted 
about one-third of the indications for removal in the 
first two years of use. Continuous progestin only 
contraceptive use alters the vaginal bleeding pattern 
and manifest as amenorrhoea, irregular bleeding 
and / or prolonged bleeding. Discontinuation of 
Implanon® due to bleeding disturbance in this study 
was 33.3%, and higher than that reported in Europe 
and Canada, 23.0% (7). This may be because our 
women are more concerned about vaginal bleeding 
and would want the implant removed in order not 
to interfere with their sexual relationships with their 
spouses. 
 Another indication for removal was the desire for 
another pregnancy. This is appropriate since majority 
of the acceptors (73.3%) were using the method as a 
temporary method of contraception. This group of 
women used the implants for an average of about 
12 months after which they indicated the desire for 
another pregnancy and the implant thus removed. 
 Weight gain constituted another important 
indication for removal. This was in 13.3% of the clients. 
There was a mean increase in weight from 64.8 kg at 
insertion to 66.7 kg at removal of the implants (1.9 kg) in 
this study. Women are concerned about weight increase 
and will have it removed if this causes weight gain. 
Body weight is increasingly becoming an indication 
for removal of the implant. In another study, the mean 
body weight gain over a two year period observed a 
mean body weight of 2.4% and 2.9% for the intrauterine 
contraceptive device and Norplant respectively, and 
suggested that the body weight gain observed with 
lmplanon® may not be much different from normal 
weight gain in women not exposed to exogenous sex 
steroids (8). That study however observed that the use 
of lmplanon® for several years has a slight tendency 
to increase in body weight. 
 Two clients (6.7%) were actually pregnant 
before the insertion. The clients said they had 
menstruated just before they came for the implant. 
However, the pregnancy continued and they had 
to report back to the clinic. Ultrasound dating of 
the pregnancies confirmed that the pregnancies 
pre-dated the lmplanon® insertion. The clients were 
further counselled and they opted to continue with 
the pregnancies by booking for antenatal care after 
removal of the implants. This brings about issues 
regarding screening of prospective clients for the 
implants and other contraceptive methods. The 
implants should be inserted within seven days of 
commencement of a normal menstrual period (1). In 
doubtful cases, chemical pregnancy should be ruled 
out by estimation of β-HCG in serum where available. 
Otherwise, postpone insertion for a menstrual cycle 
when urinary pregnancy test would have become 
positive or ultrasound scan with a vaginal probe 
may demonstrate gestational sac. There was one 
method failure as an indication for removal. This 
client was on Rifampicin for treatment of tuberculosis 
and discontinued the use of the condom contrary to 
advice from the physician. 
 Husband's disapproval of the method was the 
indication for removal in 6.7% of the clients. Headaches 
in combination with weight gain were the indication 
for removal in 6.7% of the clients. Other indications 
for removal, one in each case included acne, divorce, 
threats by mother-in-law and request by cardiologist 
and following hysterectomy. Some of the clients had 
more than one indication for removal of the implant. 
Social indications for discontinuation appear to be 
increasing among these clients. Husband, mother-in-
law and divorce contributed over 13% of the indications 
for discontinuation. This is alarming and requires 
that the male involvement should be incorporated 
in counselling issues regarding the implants. The 
disruption of the menstrual cycle, specifically 
prolonged menstrual loss may be a factor here since 
it interferes with coital pattern for the male. 
 A study has reported arm pain as an indication 
for removal of  Norplant implants (9). This was not 
reported in this series. The reason for the non-reporting 
of this may be the small number of clients and the 
relatively short duration of use in these clients. 
 In conclusion, subjective side effects that lead to 
the discontinuation of Implanon® are similar to those 
of Norplant. Menstrual disruption is still the most 
common concern of majority of the clients. Inadvertent 
insertion of the implant when a client is pregnant is 
an issue worth taking seriously. When in doubt, client 
should be given another method of contraception 
and be re-evaluated after another menstrual cycle 
for pregnancy. The client should however be placed 
on a barrier method of contraception to avoid an 
unwanted pregnancy during the period of waiting. 
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 Social issues are also indicators for discontinuation 
and require male involvement during counselling if 
this aspect is to be reduced or eliminated. 
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